The Quick ratio of QSAM Biosciences, Inc. is 0.18
Quick ratio is liquidity ratio that measures a company’s ability to use its quick assets to meet its short-term obligations immediately.
mrq (most recent quarter)
The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.
QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.